                                                                                                                                   I




                                  113TH CONGRESS
                                     1ST SESSION                          H. R. 611
                                  To provide for the expansion of Federal efforts concerning the prevention,
                                      education, treatment, and research activities related to Lyme and other
                                      tick-borne diseases, including the establishment of a Tick-Borne Diseases
                                      Advisory Committee.




                                                IN THE HOUSE OF REPRESENTATIVES
                                                            FEBRUARY 12, 2013
                                  Mr. SMITH of New Jersey (for himself, Mr. WOLF, Mr. GIBSON, and Mr.
                                      PETERSON) introduced the following bill; which was referred to the Com-
                                      mittee on Energy and Commerce




                                                                            A BILL
                                  To provide for the expansion of Federal efforts concerning
                                     the prevention, education, treatment, and research activi-
                                     ties related to Lyme and other tick-borne diseases, in-
                                     cluding the establishment of a Tick-Borne Diseases Advi-
                                     sory Committee.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Lyme and Tick-Borne
                                    5 Diseases Prevention, Education, and Research Act of




                                    6 2013’’.                                            2
                                    1     SEC. 2. ESTABLISHMENT OF A TICK-BORNE DISEASES ADVI-
                                    2                             SORY COMMITTEE.
                                    3              (a) ESTABLISHMENT.—Not later than 180 days after
                                    4 the date of the enactment of this Act, the Secretary of
                                    5 Health and Human Services (referred to in this Act as
                                    6 the ‘‘Secretary’’) shall establish within the Office of the
                                    7 Secretary an advisory committee to be known as the Tick-
                                    8 Borne Diseases Advisory Committee (referred to in this
                                    9 section as the ‘‘Committee’’).
                                  10               (b) DUTIES.—The Committee shall advise the Sec-
                                  11 retary and the Assistant Secretary for Health regarding
                                  12 the manner in which such officials can—
                                  13                         (1) ensure interagency coordination and com-
                                  14               munication and minimize overlap regarding efforts
                                  15               to address tick-borne diseases;
                                  16                         (2) identify opportunities to coordinate efforts
                                  17               with other Federal agencies and private organiza-
                                  18               tions addressing such diseases;
                                  19                         (3) ensure interagency coordination and com-
                                  20               munication with constituency groups;
                                  21                         (4) ensure that a broad spectrum of scientific
                                  22               viewpoints is represented in public health policy deci-
                                  23               sions and that information disseminated to the pub-
                                  24               lic and physicians is balanced; and





                                  25                         (5) advise relevant Federal agencies on prior-
                                  26               ities related to the Lyme and tick-borne diseases.
                                              •HR 611 IH

                                    1              (c) MEMBERSHIP.—                        3
                                    2                        (1) APPOINTED               MEMBERS.—

                                    3                                 (A) IN       GENERAL.—The                    Secretary shall ap-
                                    4                        point the voting members of the Committee
                                    5                        from among individuals who are not officers or
                                    6                        employees of the Federal Government.
                                    7                                 (B) GROUPS.—The voting members of the
                                    8                        Committee shall include the following:
                                    9                                        (i) At least 4 members from the sci-
                                  10                                  entific community representing the broad
                                  11                                  spectrum of viewpoints held within the sci-
                                  12                                  entific community related to Lyme and
                                  13                                  other tick-borne diseases.
                                  14                                         (ii) At least 2 representatives of tick-
                                  15                                  borne disease voluntary organizations.
                                  16                                         (iii) At least 2 health care providers,
                                  17                                  including at least 1 full-time practicing
                                  18                                  physician, with relevant experience pro-
                                  19                                  viding care for individuals with a broad
                                  20                                  range of acute and chronic tick-borne dis-
                                  21                                  eases.
                                  22                                         (iv) At least 2 patient representatives
                                  23                                  who are individuals who have been diag-
                                  24                                  nosed with a tick-borne disease or who





                                              •HR 611 IH

                                                                                             4
                                    1                                 have had an immediate family member di-
                                    2                                 agnosed with such a disease.
                                    3                                        (v) At least 2 representatives of State
                                    4                                 and local health departments and national
                                    5                                 organizations that represent State and
                                    6                                 local health professionals.
                                    7                                 (C) DIVERSITY.—In appointing members
                                    8                        under this paragraph, the Secretary shall en-
                                    9                        sure that such members, as a group, represent
                                  10                         a diversity of scientific perspectives relevant to
                                  11                         the duties of the Committee.
                                  12                         (2) EX           OFFICIO            MEMBERS.—The                      Secretary
                                  13               shall designate, as nonvoting, ex officio members of
                                  14               the Committee, representatives overseeing tick-borne
                                  15               disease activities from each of the following Federal
                                  16               agencies:
                                  17                                  (A) The Centers for Disease Control and
                                  18                         Prevention.
                                  19                                  (B) The National Institutes of Health.
                                  20                                  (C) The Agency for Healthcare Research
                                  21                         and Quality.
                                  22                                  (D) The Food and Drug Administration.
                                  23                                  (E) The Office of the Assistant Secretary
                                  24                         for Health.





                                              •HR 611 IH

                                                                                             5
                                    1                                 (F) Such additional Federal agencies as
                                    2                        the Secretary determines to be appropriate.
                                    3                        (3) CO-CHAIRPERSONS.—The Secretary shall
                                    4              designate the Assistant Secretary of Health as the
                                    5              co-chairperson of the Committee. The appointed
                                    6              members of the Committee shall also elect a public
                                    7              co-chairperson. The public co-chairperson shall serve
                                    8              a 2-year term.
                                    9                        (4) TERM              OF        APPOINTMENT.—The                      term of
                                  10               service for each member of the Committee appointed
                                  11               under paragraph (1) shall be 4 years.
                                  12                         (5) VACANCY.—A vacancy in the membership of
                                  13               the Committee shall be filled in the same manner as
                                  14               the original appointment. Any member appointed to
                                  15               fill a vacancy for an unexpired term shall be ap-
                                  16               pointed for the remainder of that term. Members
                                  17               may serve after the expiration of their terms until
                                  18               their successors have taken office.
                                  19               (d) MEETINGS.—The Committee shall hold public
                                  20 meetings, except as otherwise determined by the Sec-
                                  21 retary, after providing notice to the public of such meet-
                                  22 ings, and shall meet at least twice a year with additional
                                  23 meetings subject to the call of the co-chairpersons. Agenda
                                  24 items with respect to such meetings may be added at the




                                  25 request of the members of the Committee, including the
                                              •HR 611 IH

                                                                                             6
                                    1 co-chairpersons. Meetings shall be conducted, and records
                                    2 of the proceedings shall be maintained, as required by ap-
                                    3 plicable law and by regulations of the Secretary.
                                    4              (e) REPORT.—Not later than 1 year after the date
                                    5 of the enactment of this Act, and annually thereafter, the
                                    6 Committee, through the Director of the Centers for Dis-
                                    7 ease Control and Prevention and the Director of the Na-
                                    8 tional Institutes of Health, shall submit a report to the
                                    9 Secretary. Each such report shall contain, at a min-
                                  10 imum—
                                  11                         (1) a description of the Committee’s functions;
                                  12                         (2) a list of the Committee’s members and their
                                  13               affiliations; and
                                  14                         (3) a summary of the Committee’s activities
                                  15               and recommendations during the previous year, in-
                                  16               cluding any significant issues regarding the func-
                                  17               tioning of the Committee.
                                  18               (f) AUTHORIZATION                         OF   APPROPRIATIONS.—For the
                                  19 purpose of carrying out this section, there is authorized
                                  20 to be appropriated $250,000 for each of fiscal years 2014
                                  21 through 2018. Amounts appropriated under the preceding
                                  22 sentence shall be used for the expenses and per diem costs
                                  23 incurred by the Committee under this section in accord-
                                  24 ance with the Federal Advisory Committee Act, except





                                              •HR 611 IH

                                                                                             7
                                    1 that no voting member of the Committee shall be a perma-
                                    2 nent salaried employee.
                                    3     SEC. 3. FEDERAL ACTIVITIES RELATED TO THE DIAGNOSIS,
                                    4                             SURVEILLANCE,                     PREVENTION,                    AND   RE-
                                    5                             SEARCH OF LYME AND OTHER TICK-BORNE
                                    6                             DISEASES.
                                    7              (a) IN GENERAL.—The Secretary, acting as appro-
                                    8 priate through the Director of the Centers for Disease
                                    9 Control and Prevention, the Director of the National Insti-
                                  10 tutes of Health, the Commissioner of Food and Drugs,
                                  11 and the Director of the Agency for Healthcare Research
                                  12 and Quality, as well as additional Federal agencies as the
                                  13 Secretary determines to be appropriate, and in consulta-
                                  14 tion with the Tick-Borne Diseases Advisory Committee,
                                  15 shall provide for—
                                  16                         (1) the conduct or support of activities de-
                                  17               scribed in paragraphs (1) through (4) of subsection
                                  18               (b); and
                                  19                         (2) the coordination of all Federal programs
                                  20               and activities related to Lyme disease and other
                                  21               tick-borne diseases.
                                  22               (b) ACTIVITIES.—The activities to be conducted or
                                  23 supported under subsection (a) include the following:
                                  24          •HR 611 IH   (1) DEVELOPMENT                 8   OF DIAGNOSTIC TESTS.—
                                    1                                 (A) The development of sensitive and more
                                    2                        accurate diagnostic tools and tests, including a
                                    3                        direct detection test for Lyme disease capable
                                    4                        of distinguishing active infection from past in-
                                    5                        fection.
                                    6                                 (B) Improving the efficient utilization of
                                    7                        diagnostic testing currently available to account
                                    8                        for the multiple clinical manifestations of both
                                    9                        acute and chronic Lyme disease.
                                  10                                  (C) Providing for the timely evaluation of
                                  11                         promising emerging diagnostic methods.
                                  12                         (2) SURVEILLANCE                    AND REPORTING.—

                                  13                                  (A) Accurately determining the prevalence
                                  14                         of Lyme and other tick-borne disease.
                                  15                                  (B) Evaluating the feasibility of developing
                                  16                         a reporting system for the collection of data on
                                  17                         physician-diagnosed cases of Lyme disease that
                                  18                         do not meet the surveillance criteria of the Cen-
                                  19                         ters for Disease Control and Prevention in
                                  20                         order to more accurately gauge disease inci-
                                  21                         dence.
                                  22                                  (C) Evaluating the feasibility of creating a
                                  23                         national uniform reporting system including re-
                                  24                         quired reporting by laboratories in each State.





                                  25                         (3) PREVENTION.—


                                              •HR 611 IH

                                                                                             9
                                    1                                 (A) The provision and promotion of access
                                    2                        to a comprehensive, up-to-date clearinghouse of
                                    3                        peer-reviewed information on Lyme and other
                                    4                        tick-borne disease.
                                    5                                 (B) Increased public education related to
                                    6                        Lyme and other tick-borne diseases through the
                                    7                        expansion of the community-based education
                                    8                        programs of the Centers for Disease Control
                                    9                        and Prevention to include expansion of informa-
                                  10                         tion access points to the public.
                                  11                                  (C) The creation of a physician education
                                  12                         program that includes the full spectrum of sci-
                                  13                         entific research related to Lyme and other tick-
                                  14                         borne diseases.
                                  15                                  (D) The sponsoring of scientific con-
                                  16                         ferences on Lyme and other tick-borne diseases,
                                  17                         including reporting and consideration of the full
                                  18                         spectrum of clinically based knowledge, with the
                                  19                         first of such conferences to be held not later
                                  20                         than 24 months after the date of the enactment
                                  21                         of this Act.
                                  22                         (4) CLINICAL             OUTCOMES RESEARCH.—

                                  23                                  (A) The establishment of epidemiological
                                  24                         research objectives to determine the long-term




                                  25                         course of illness for Lyme disease.
                                              •HR 611 IH

                                                                                         10
                                    1                                 (B) Determination of the effectiveness of
                                    2                        different treatment modalities by establishing
                                    3                        treatment outcome objectives.
                                    4              (c) AUTHORIZATION                         OF   APPROPRIATIONS.—For the
                                    5 purposes of carrying out this section and providing for ad-
                                    6 ditional research, prevention, and educational activities for
                                    7 Lyme and other tick-borne diseases, there is authorized
                                    8 to be appropriated $20,000,000 for each of fiscal years
                                    9 2014 through 2018. Such authorization of appropriations
                                  10 is in addition to any other authorization of appropriations
                                  11 available for such purpose. Of the amounts authorized to
                                  12 be appropriated under this subsection—
                                  13                         (1) for fiscal year 2014, at least $7,500,000
                                  14               shall be for activities of the Centers for Disease Con-
                                  15               trol and Prevention; and
                                  16                         (2) for each of fiscal years 2015 through 2018,
                                  17               at least $5,000,000 shall be for activities of the Cen-
                                  18               ters for Disease Control and Prevention.
                                  19      SEC. 4. REPORTS ON LYME AND OTHER TICK-BORNE DIS-
                                  20                              EASES.
                                  21               (a) IN GENERAL.—Not later than 18 months after
                                  22 the date of the enactment of this Act, and annually there-
                                  23 after, the Secretary shall submit to the Congress a report
                                  24 on the activities carried out under this Act.





                                              •HR 611 IH

                                                                                         11
                                    1              (b) CONTENT.—Reports under subsection (a) shall
                                    2 contain—
                                    3                        (1) a description of significant activities or de-
                                    4              velopments related to the surveillance, diagnosis,
                                    5              treatment, education, or prevention of Lyme or other
                                    6              tick-borne diseases, including suggestions for further
                                    7              research and education;
                                    8                        (2) a scientifically qualified assessment of Lyme
                                    9              and other tick-borne diseases, including both acute
                                  10               and chronic instances, related to the broad spectrum
                                  11               of empirical evidence of treating physicians, as well
                                  12               as published peer-reviewed data, that shall include
                                  13               recommendations for addressing research gaps in di-
                                  14               agnosis and treatment of Lyme and other tick-borne
                                  15               diseases and an evaluation of treatment guidelines
                                  16               and their utilization;
                                  17                         (3) a description of progress in the development
                                  18               of accurate diagnostic tools that are more useful in
                                  19               the clinical setting for both acute and chronic dis-
                                  20               ease;
                                  21                         (4) a description of activities for the promotion
                                  22               of public awareness and physician education initia-
                                  23               tives to improve the knowledge of health care pro-
                                  24               viders and the public regarding clinical and surveil-





                                              •HR 611 IH

                                                                                         12
                                    1              lance practices for Lyme disease and other tick-
                                    2              borne diseases; and
                                    3                        (5) a copy of the most recent annual report
                                    4              issued by the Tick-Borne Diseases Advisory Com-
                                    5              mittee established in section 2 and an assessment of
                                    6              progress in achieving recommendations of that Com-
                                    7              mittee.
                                              •HR 611 IH                                   Æ
